Lornoxicam

Lornoxicam is a non steroidal anti-inflammatory drug with analgesic properties and belongs to the class of oxicams. Lornoxicam's mode of action is partly based on inhibition of the prostaglandin synthesis (inhibition of the cyclooxygenase enzyme).

Lornoxicam is primarily indicated in conditions like Ankylosing spondylitis, Osteoarthritis, Pain, Rheumatic arthritis.

Lornoxicam is contraindicated in conditions like Hypovolaemia,Peptic ulcer,Cardiac insufficiency,Hypersensitivity,Pregnancy,Lactation,Gastrointestinal hemorrhage,Severe renal impairment,Dehydration,Hepatic impairment,Cerebrovascular hemorrhage.

The severe or irreversible adverse effects of Lornoxicam, which give rise to further complications include Anemia, Anemia, Thrombocytopenia, Skin reactions, Leucopenia, Hypertension, Palpitation, Anemia, Hypersensitivity.Lornoxicam produces potentially life-threatening effects which include Hypersensitivity, Gastrointestinal hemorrhage. which are responsible for the discontinuation of Lornoxicam therapy.The signs and symptoms that are produced after the acute overdosage of Lornoxicam include Nausea, Vomiting, Coma, Ataxia, Dizziness, Coagulopathy, Renal damage.The symptomatic adverse reactions produced by Lornoxicam are more or less tolerable and if they become severe, they can be treated symptomatically, these include Flatulence, Dizziness, Vertigo, Headache, Drowsiness, Diarrhea, Myalgia, Tachycardia, Constipation, Insomnia, Nervousness, Tinnitus, Abdominal pain, Dry mouth, Urticaria, Dyspepsia, Hypotension, Depression, Somnolence, Cough, Nausea and vomiting, Rhinitis, Agitation, Leg cramps, Hypertension, nervousness.

Gastrointestinal ulceration and bleeding in medical history: Clinical monitoring at regular intervals is recommended in patients developing peptic ulceration and/or gastrointestinal bleeding while taking Lornoxicam should discontinue drug administration and with appropriate therapeutic actions being taken. Mild renal impairment (Serum creatinine 150 - 300 micro mol/L) should be monitored quarterly, patients with moderate renal impairment (Serum creatinine 300 - 700 micro mol/L) should be monitored in 1 to 2 months intervals. Careful clinical monitoring and laboratory assessment is recommended in liver diseases, blood coagulation disorders, cardiac failure. In case of long term treatment, longer than three months and in elderly patients with age greater than 65 years regular lab assessments of renal function and liver enzymes is recommended. monitor renal function in patients who are to undergo major surgery, with stressed renal function and cardiac failure and receiving concomitant diuretics treatment.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

4 to 6 mg (5 (5)) 3 hourly oral — for osteoarthritis and rheumatoid arthritis 8 to 16 mg (12 (12)) 12 hourly oral — Pain 8 to 24 mg (16 (16)) As recommended. IVor IM — limited upto two days, for treatment of osteo arthritis and rheumatoid arthritis

( ) — Not recommended in this age group

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Lornoxicam was found.

Store at room temperature, .